Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07144384 2026-02-13

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

40 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

22 enrolled

Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

14 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT07389525 2026-02-05

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Phase EARLY_PHASE1 Not yet recruiting

80 enrolled

DermatologicGastrointestinalSarcoma

Gastrointestinal Neoplasms, Melanoma, Sarcoma, Urogenital Neoplasms

NCT05098184 2025-12-11

A Study of GC101 TIL in Advanced Melanoma (10hospital)

Phase EARLY_PHASE1 Recruiting

50 enrolled

Dermatologic

Advanced Melanoma

NCT06472661 2025-11-20

Mel 70

Phase EARLY_PHASE1 Recruiting

11 enrolled

Dermatologic

Melanoma

NCT07213882 2025-10-09

CITY

Phase EARLY_PHASE1 Not yet recruiting

30 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT06664151 2025-10-02

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Phase EARLY_PHASE1 Recruiting

25 enrolled

Dermatologic

Skin Neoplasms

NCT05279027 2025-09-19

Zr89 + PET Companion Trial

Phase EARLY_PHASE1 Completed

6 enrolled

Dermatologic

Melanoma

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Phase EARLY_PHASE1 Completed

11 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT04581382 2025-07-10

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Phase EARLY_PHASE1 Completed

18 enrolled

Dermatologic

Melanoma

Clinical Trials

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

CivaDerm(TM) Surface Therapy Pilot Study

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

A Study of GC101 TIL in Advanced Melanoma (10hospital)

Mel 70

CITY

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Zr89 + PET Companion Trial

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma